The effects of raloxifene and tibolone on homocysteine and vascular histopathological changes

Basit Öğe Kaydı
dc.contributor.authorBayram, M.
dc.contributor.authorÖzer, G.
dc.contributor.authorKalender, H.
dc.contributor.authorKabakcı, N.
dc.contributor.authorKısa, Üçler
dc.contributor.authorÖzkan, Y.
dc.date.accessioned2020-06-25T17:43:34Z
dc.date.available2020-06-25T17:43:34Z
dc.date.issued2007
dc.descriptionKISA, Ucler/0000-0002-8131-6810; OZKAN, YESIM/0000-0002-1669-4962
dc.description.abstractThe aim of the present study was to examine the effects of raloxifene (RLX) and tibolone (TBN) on plasma homocysteine (Hey) levels and their relationship with atherosclerotic changes in the walls of the carotid artery in ovariectomised rats. Thirty surgically ovariectomised Wistar albino rats after a menopausal period of 6 cycles were randomly assigned to receive RLX 0.01 mg/kg/day (n=10), TBN 0.04 mg/kg/day (n=10) and the same dose of placebo (n=10) for 6 cycles. Serum levels of vitamin B12, folate and Hey were measured and carotid arteries were examined histopathologically following the termination of treatment. Hey levels were 3.27 +/- 0.97, 2.57 +/- 0.32 and 2.28 +/- 0.12 mu mol/l, Vitamin B12 levels were 901.90 +/- 239.76, 694.70 +/- 112.20 and 631 +/- 309.44 pg/ml and folate levels were 73.80 +/- 12.71, 72.51 +/- 7.05 and 84.79 +/- 20.82 ng/ml in receiving RLX, TBN and placebo respectively. Hey levels were increased by RLX vs. placebo (P=0.006) but not by TBN vs. placebo (P=0.070). Vitamin B 12 levels were found to be elevated by TBN vs. the control group (P=0.041) but not by RLX vs. placebo (P=0.059). Histopathological examination of carotid arteries from rats receiving both RLX and TBN revealed no difference vs. placebo. Data obtained from the study support the view that neither RLX nor TBN appears to have a primary protective effect on vascular disease by effecting the metabolism of Hey at menopause.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1007/s10238-007-0139-6
dc.identifier.endpage153en_US
dc.identifier.issn1591-8890
dc.identifier.issn1591-9528
dc.identifier.issue4en_US
dc.identifier.pmid18188527
dc.identifier.scopus2-s2.0-38149124774
dc.identifier.scopusqualityQ2
dc.identifier.startpage149en_US
dc.identifier.urihttps://doi.org10.1007/s10238-007-0139-6
dc.identifier.urihttps://hdl.handle.net/20.500.12587/3804
dc.identifier.volume7en_US
dc.identifier.wosWOS:000251961900004
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer-Verlag Italia Srlen_US
dc.relation.ispartofClinical And Experimental Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjecthormone replacement therapyen_US
dc.subjecttamoxifeneen_US
dc.subjectraloxifeneen_US
dc.subjecthomocysteineen_US
dc.subjectvascular histopathologyen_US
dc.titleThe effects of raloxifene and tibolone on homocysteine and vascular histopathological changesen_US
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu